The table is a review of notable updates that occurred in February 2025 for investigational products in development.

When your doctor talks to you about your B-cell lymphoma, they'll tell you what type you have. It's an important piece of info to get, because each type of this cancer acts differently and has its ...

Odronextamab is approved as Ordspono™ in the European Union for the treatment of R/R FL or diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy although its safety ...

Perspective from John Luo, MD Patients with dupilumab prescriptions for their atopic dermatitis had lower risks for psychiatric and sleep disorders than those prescribed other treatments ...

Coronary artery disease (CAD), or the narrowing of the coronary arteries, is the leading cause of morbidity and mortality throughout the world. Atherosclerosis, or the buildup of plaque in the ...

They include Sanofi/Regeneron's IL-4/IL-13 inhibitor Dupixent (dupilumab) and AZ's own IL-5 inhibitor Fasenra (benralizumab), which competes with GlaxoSmithKline's Nucala (mepolizumab) and Teva's ...

Odronextamab is approved as Ordspono™ in the European Union for the treatment of R/R FL or diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy although its safety and ...

Bongino, a former NYPD officer and Secret Service agent, is a cancer survivor who shared his battle with Hodgkin lymphoma publicly, emphasizing the importance of resilience and support.

The survival rate of non-Hodgkin’s lymphoma is generally lower than that of Hodgkin’s lymphoma, but it’s still often curable. Lymphoma is a group of cancers that start in the lymphatic system.